D
Kane Biotech Inc.
KNE.V
TSX
D
Sell
12/2/2024Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D+ from E+ on 12/2/2024 due to a significant increase in the valuation index, efficiency index and solvency index.
Kane Biotech Inc. (KNE.V) was upgraded to D+ from E+ on 12/2/2024 due to a significant increase in the valuation index, efficiency index and solvency index.
E
Sell
8/15/2024Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 8/15/2024 due to a noticeable decline in the solvency index and growth index. EBIT declined 69.76% from -$519.1 to -$881.2, debt to equity increased from -0.77 to -0.72, and the quick ratio declined from 0.08 to 0.08.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 8/15/2024 due to a noticeable decline in the solvency index and growth index. EBIT declined 69.76% from -$519.1 to -$881.2, debt to equity increased from -0.77 to -0.72, and the quick ratio declined from 0.08 to 0.08.
D
Sell
3/27/2024Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 3/27/2024 due to a noticeable increase in the volatility index and total return index.
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 3/27/2024 due to a noticeable increase in the volatility index and total return index.
E
Sell
3/11/2024Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 3/11/2024 due to a decline in the volatility index, total return index and valuation index.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 3/11/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
2/15/2024Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 2/15/2024 due to an increase in the growth index, volatility index and valuation index. Total revenue increased 9.38% from $489.3 to $535.2.
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 2/15/2024 due to an increase in the growth index, volatility index and valuation index. Total revenue increased 9.38% from $489.3 to $535.2.
E
Sell
6/29/2023Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 6/29/2023 due to a decline in the volatility index.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 6/29/2023 due to a decline in the volatility index.
D
Sell
6/8/2023Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 6/8/2023 due to an increase in the volatility index.
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 6/8/2023 due to an increase in the volatility index.
E
Sell
6/2/2023Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 6/2/2023 due to a decline in the volatility index, solvency index and valuation index. Debt to equity increased from -1.06 to -0.9, and the quick ratio declined from 0.39 to 0.34.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 6/2/2023 due to a decline in the volatility index, solvency index and valuation index. Debt to equity increased from -1.06 to -0.9, and the quick ratio declined from 0.39 to 0.34.
D
Sell
3/29/2023Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and total return index.
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D on 03/14/2023.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Kane Biotech Inc. (KNE.V) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, volatility index and growth index. Total revenue declined 33.37% from $657.7 to $438.2, operating cash flow declined 32.38% from -$574.2 to -$760.1, and EBIT declined 15.43% from -$565.7 to -$653.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, volatility index and growth index. Total revenue declined 33.37% from $657.7 to $438.2, operating cash flow declined 32.38% from -$574.2 to -$760.1, and EBIT declined 15.43% from -$565.7 to -$653.
D
Sell
5/4/2022Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Kane Biotech Inc. (KNE.V) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/3/2022Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 5/3/2022 due to a decline in the volatility index and total return index.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 5/3/2022 due to a decline in the volatility index and total return index.
D
Sell
4/20/2022Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from -1.32 to -0.94, and the quick ratio declined from 0.59 to 0.47.
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from -1.32 to -0.94, and the quick ratio declined from 0.59 to 0.47.
D
Sell
3/15/2022Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D from D+ on 3/15/2022 due to a noticeable decline in the volatility index, total return index and growth index. EBIT declined 53.89% from -$819.8 to -$1.26M, and earnings per share declined from -$0.0066 to -$0.0079.
Kane Biotech Inc. (KNE.V) was downgraded to D from D+ on 3/15/2022 due to a noticeable decline in the volatility index, total return index and growth index. EBIT declined 53.89% from -$819.8 to -$1.26M, and earnings per share declined from -$0.0066 to -$0.0079.
D
Sell
11/9/2021Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D- on 11/9/2021 due to an increase in the valuation index.
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D- on 11/9/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D- from D+ on 11/8/2021 due to a noticeable decline in the solvency index and volatility index.
Kane Biotech Inc. (KNE.V) was downgraded to D- from D+ on 11/8/2021 due to a noticeable decline in the solvency index and volatility index.
D
Sell
8/27/2021Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D on 8/27/2021 due to an increase in the valuation index and volatility index.
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D on 8/27/2021 due to an increase in the valuation index and volatility index.
D
Sell
5/1/2020Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D from D+ on 5/1/2020 due to a noticeable decline in the efficiency index.
Kane Biotech Inc. (KNE.V) was downgraded to D from D+ on 5/1/2020 due to a noticeable decline in the efficiency index.
D
Sell
4/6/2020Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D- on 4/6/2020 due to a major increase in the total return index, efficiency index and solvency index. The quick ratio increased from 0.3 to 0.94, and total capital increased 80.08% from $448.9 to $808.4.
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D- on 4/6/2020 due to a major increase in the total return index, efficiency index and solvency index. The quick ratio increased from 0.3 to 0.94, and total capital increased 80.08% from $448.9 to $808.4.
D
Sell
11/25/2019Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 11/25/2019 due to a noticeable decline in the efficiency index and total return index. Net income declined 149.68% from $1.25M to -$622.2, and total capital declined 59.15% from $1.1M to $448.9.
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 11/25/2019 due to a noticeable decline in the efficiency index and total return index. Net income declined 149.68% from $1.25M to -$622.2, and total capital declined 59.15% from $1.1M to $448.9.
D
Sell
8/22/2019Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D from C- on 8/22/2019 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from -0.97 to 30.08.
Kane Biotech Inc. (KNE.V) was downgraded to D from C- on 8/22/2019 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from -0.97 to 30.08.
C
Hold
6/7/2019Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to C- from D+ on 6/7/2019 due to an increase in the valuation index, total return index and growth index.
Kane Biotech Inc. (KNE.V) was upgraded to C- from D+ on 6/7/2019 due to an increase in the valuation index, total return index and growth index.
D
Sell
5/23/2019Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D- on 5/23/2019 due to a significant increase in the efficiency index, growth index and total return index. Total revenue increased 196.89% from $157.4 to $467.3, operating cash flow increased 35.67% from -$457.5 to -$294.3, and net income increased 3% from -$509.8 to -$494.5.
Kane Biotech Inc. (KNE.V) was upgraded to D+ from D- on 5/23/2019 due to a significant increase in the efficiency index, growth index and total return index. Total revenue increased 196.89% from $157.4 to $467.3, operating cash flow increased 35.67% from -$457.5 to -$294.3, and net income increased 3% from -$509.8 to -$494.5.
D
Sell
4/15/2019Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 4/15/2019 due to a major decline in the efficiency index.
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 4/15/2019 due to a major decline in the efficiency index.
D
Sell
3/29/2019Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D from D- on 3/29/2019 due to a major increase in the efficiency index and volatility index. Net income increased 33.14% from -$762.5 to -$509.8.
Kane Biotech Inc. (KNE.V) was upgraded to D from D- on 3/29/2019 due to a major increase in the efficiency index and volatility index. Net income increased 33.14% from -$762.5 to -$509.8.
D
Sell
5/4/2017Upgraded
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 5/4/2017 due to an increase in the valuation index.
Kane Biotech Inc. (KNE.V) was upgraded to D- from E+ on 5/4/2017 due to an increase in the valuation index.
E
Sell
4/19/2017Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 4/19/2017 due to a large decline in the total return index, valuation index and volatility index.
Kane Biotech Inc. (KNE.V) was downgraded to E+ from D- on 4/19/2017 due to a large decline in the total return index, valuation index and volatility index.
D
Sell
3/11/2016Downgrade
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 3/11/2016 due to a significant decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 0.77 to 0.95, the quick ratio declined from 0.52 to 0.41, and net income declined 16.25% from -$270.8 to -$314.8.
Kane Biotech Inc. (KNE.V) was downgraded to D- from D on 3/11/2016 due to a significant decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 0.77 to 0.95, the quick ratio declined from 0.52 to 0.41, and net income declined 16.25% from -$270.8 to -$314.8.
